BCL2 and ITPR1 |
B-cell CLL/lymphoma 2 |
inositol 1,4,5-trisphosphate receptor, type 1 |
- Activation of BAD and translocation to mitochondria
- Inflammasomes
- The NLRP1 inflammasome
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Programmed Cell Death
- Activation of BH3-only proteins
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Innate Immune System
- Intrinsic Pathway for Apoptosis
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- Integration of energy metabolism
- cGMP effects
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Effects of PIP2 hydrolysis
- Platelet calcium homeostasis
- DAP12 signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- Role of phospholipids in phagocytosis
- Fcgamma receptor (FCGR) dependent phagocytosis
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- G alpha (q) signalling events
- Signaling by EGFR
- GPCR downstream signaling
- Platelet homeostasis
- Signaling by VEGF
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- G alpha (q) signalling events
- DAG and IP3 signaling
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Downstream signaling of activated FGFR
- Nitric oxide stimulates guanylate cyclase
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- PLC beta mediated events
- Regulation of insulin secretion
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- beta-catenin independent WNT signaling
- Signaling by FGFR
- Ca2+ pathway
- Elevation of cytosolic Ca2+ levels
- PLC-gamma1 signalling
- FCERI mediated Ca+2 mobilization
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
|
|
|
|
BCL2 and HRAS |
B-cell CLL/lymphoma 2 |
Harvey rat sarcoma viral oncogene homolog |
- Activation of BAD and translocation to mitochondria
- Inflammasomes
- The NLRP1 inflammasome
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Programmed Cell Death
- Activation of BH3-only proteins
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Innate Immune System
- Intrinsic Pathway for Apoptosis
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- SHC-mediated cascade
- MEK activation
- FCERI mediated MAPK activation
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- p38MAPK events
- EPH-Ephrin signaling
- SOS-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- SHC-mediated signalling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-2 signaling
- Interleukin-3, 5 and GM-CSF signaling
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Ras activation uopn Ca2+ infux through NMDA receptor
- Adaptive Immune System
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- IRS-mediated signalling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- IRS-related events triggered by IGF1R
- EGFR Transactivation by Gastrin
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- RAF phosphorylates MEK
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Post NMDA receptor activation events
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- SHC-mediated signalling
- IRS-related events
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- ARMS-mediated activation
- SHC1 events in EGFR signaling
- RAF activation
- IRS-mediated signalling
- FRS2-mediated cascade
- Activation of RAS in B cells
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- Constitutive Signaling by EGFRvIII
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
|
- Hexane-1,6-Diol
- Trifluoroethanol
- Guanosine-5\'-Triphosphate
- Guanosine-5\'-Diphosphate
- N,N\'-DIMETHYL-N-(ACETYL)-N\'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
|
|
|
BCL2 and KRAS |
B-cell CLL/lymphoma 2 |
Kirsten rat sarcoma viral oncogene homolog |
- Activation of BAD and translocation to mitochondria
- Inflammasomes
- The NLRP1 inflammasome
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Programmed Cell Death
- Activation of BH3-only proteins
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Innate Immune System
- Intrinsic Pathway for Apoptosis
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- SHC-mediated cascade
- MEK activation
- FCERI mediated MAPK activation
- Signaling by EGFRvIII in Cancer
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Gastrin-CREB signalling pathway via PKC and MAPK
- p38MAPK events
- SOS-mediated signalling
- SHC-mediated signalling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Signaling by VEGF
- Downstream signal transduction
- Signalling to RAS
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Frs2-mediated activation
- Signaling by Leptin
- Adaptive Immune System
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- IRS-mediated signalling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- IRS-related events triggered by IGF1R
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- VEGFR2 mediated cell proliferation
- RAF phosphorylates MEK
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- ARMS-mediated activation
- RAF activation
- SHC1 events in EGFR signaling
- IRS-mediated signalling
- Activation of RAS in B cells
- FRS2-mediated cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Constitutive Signaling by EGFRvIII
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
|
|
|
|
BCL2 and NRAS |
B-cell CLL/lymphoma 2 |
neuroblastoma RAS viral (v-ras) oncogene homolog |
- Activation of BAD and translocation to mitochondria
- Inflammasomes
- The NLRP1 inflammasome
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Programmed Cell Death
- Activation of BH3-only proteins
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Innate Immune System
- Intrinsic Pathway for Apoptosis
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- SHC-mediated cascade
- MEK activation
- FCERI mediated MAPK activation
- Signaling by EGFRvIII in Cancer
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Gastrin-CREB signalling pathway via PKC and MAPK
- p38MAPK events
- SOS-mediated signalling
- SHC-mediated signalling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Signaling by VEGF
- Downstream signal transduction
- Signalling to RAS
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Frs2-mediated activation
- Signaling by Leptin
- Adaptive Immune System
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- IRS-mediated signalling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- IRS-related events triggered by IGF1R
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- VEGFR2 mediated cell proliferation
- RAF phosphorylates MEK
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- ARMS-mediated activation
- RAF activation
- SHC1 events in EGFR signaling
- IRS-mediated signalling
- Activation of RAS in B cells
- FRS2-mediated cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Constitutive Signaling by EGFRvIII
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
|
|
|
|
BCL9 and PYGO2 |
B-cell CLL/lymphoma 9 |
pygopus family PHD finger 2 |
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
- deactivation of the beta-catenin transactivating complex
|
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
- deactivation of the beta-catenin transactivating complex
|
|
|
|
|
BCL9 and CTNNB1 |
B-cell CLL/lymphoma 9 |
catenin (cadherin-associated protein), beta 1, 88kDa |
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
- deactivation of the beta-catenin transactivating complex
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
BRCA1 and NRIP1 |
breast cancer 1, early onset |
nuclear receptor interacting protein 1 |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
|
|
|
|
|
BRCA1 and ESR1 |
breast cancer 1, early onset |
estrogen receptor 1 |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- Nuclear signaling by ERBB4
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
- Signaling by ERBB4
|
|
- Diethylstilbestrol
- Chlorotrianisene
- Conjugated Estrogens
- Etonogestrel
- Desogestrel
- Levonorgestrel
- Progesterone
- Raloxifene
- Toremifene
- Medroxyprogesterone
- Estrone
- Tamoxifen
- Estradiol
- Ethynodiol Diacetate
- Clomifene
- Dienestrol
- Fulvestrant
- Norgestimate
- Ethinyl Estradiol
- Melatonin
- Trilostane
- Naloxone
- Fluoxymesterone
- Estramustine
- Mestranol
- Danazol
- Allylestrenol
- Genistein
- Compound 19
- Compound 18
- Compound 4-D
- 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Estriol
- Estropipate
- Quinestrol
- Ospemifene
- 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
- 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
- (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
- (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
- 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
- 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
- DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
- 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
- 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
- RALOXIFENE CORE
|
|
|
BRCA1 and ETV5 |
breast cancer 1, early onset |
ets variant 5 |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
|
|
|
|
|
BRCA1 and TRRAP |
breast cancer 1, early onset |
transformation/transcription domain-associated protein |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- Chromatin modifying enzymes
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
- HATs acetylate histones
|
|
|
|
|
BRCA1 and MAP3K1 |
breast cancer 1, early onset |
mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- FCERI mediated MAPK activation
- Toll Like Receptor TLR6:TLR2 Cascade
- Toll Like Receptor 2 (TLR2) Cascade
- Toll Like Receptor TLR1:TLR2 Cascade
- Activated TLR4 signalling
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll-Like Receptors Cascades
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 10 (TLR10) Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- MyD88 dependent cascade initiated on endosome
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
|
|
|
|
|
BRCA1 and HIST1H2AB |
breast cancer 1, early onset |
histone cluster 1, H2ab |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- RNA Polymerase I Chain Elongation
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Mitotic Prophase
- Regulatory RNA pathways
- RNA Polymerase I Promoter Clearance
- Deposition of new CENPA-containing nucleosomes at the centromere
- Cellular Senescence
- Signaling by Wnt
- HATs acetylate histones
- M Phase
- Amyloids
- NoRC negatively regulates rRNA expression
- Packaging Of Telomere Ends
- Telomere Maintenance
- Nucleosome assembly
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- DNA methylation
- Transcriptional regulation by small RNAs
- Meiotic recombination
- DNA Damage/Telomere Stress Induced Senescence
- Chromosome Maintenance
- HDACs deacetylate histones
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- RNA Polymerase I Transcription
- formation of the beta-catenin:TCF transactivating complex
- Meiotic synapsis
- Epigenetic regulation of gene expression
- Senescence-Associated Secretory Phenotype (SASP)
- Negative epigenetic regulation of rRNA expression
- PRC2 methylates histones and DNA
- Cell Cycle, Mitotic
- RMTs methylate histone arginines
- Chromatin modifying enzymes
- Oxidative Stress Induced Senescence
- TCF dependent signaling in response to WNT
- RNA Polymerase I Promoter Opening
- SIRT1 negatively regulates rRNA Expression
- Signaling by WNT in cancer
- Condensation of Prophase Chromosomes
|
|
|
|
|
BRCA1 and HIST2H2AC |
breast cancer 1, early onset |
histone cluster 2, H2ac |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- RNA Polymerase I Chain Elongation
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Mitotic Prophase
- Regulatory RNA pathways
- RNA Polymerase I Promoter Clearance
- Deposition of new CENPA-containing nucleosomes at the centromere
- Cellular Senescence
- Signaling by Wnt
- HATs acetylate histones
- M Phase
- Amyloids
- NoRC negatively regulates rRNA expression
- Packaging Of Telomere Ends
- Telomere Maintenance
- Nucleosome assembly
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- DNA methylation
- Transcriptional regulation by small RNAs
- Meiotic recombination
- DNA Damage/Telomere Stress Induced Senescence
- Chromosome Maintenance
- HDACs deacetylate histones
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- RNA Polymerase I Transcription
- formation of the beta-catenin:TCF transactivating complex
- Meiotic synapsis
- Epigenetic regulation of gene expression
- Senescence-Associated Secretory Phenotype (SASP)
- Negative epigenetic regulation of rRNA expression
- PRC2 methylates histones and DNA
- Cell Cycle, Mitotic
- RMTs methylate histone arginines
- Chromatin modifying enzymes
- Oxidative Stress Induced Senescence
- TCF dependent signaling in response to WNT
- RNA Polymerase I Promoter Opening
- SIRT1 negatively regulates rRNA Expression
- Signaling by WNT in cancer
- Condensation of Prophase Chromosomes
|
|
|
|
|
BRCA1 and FAM175A |
breast cancer 1, early onset |
family with sequence similarity 175, member A |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
|
|
|
|
|
BRCA1 and MLH1 |
breast cancer 1, early onset |
mutL homolog 1 |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- Meiotic recombination
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
- Mismatch Repair
|
|
|
|
|
BRCA1 and NCOA2 |
breast cancer 1, early onset |
nuclear receptor coactivator 2 |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- PPARA activates gene expression
- Bile acid and bile salt metabolism
- Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
- Organelle biogenesis and maintenance
- Metabolism of lipids and lipoproteins
- Metabolic disorders of biological oxidation enzymes
- Phase 1 - Functionalization of compounds
- Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
- RORA activates circadian gene expression
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
- Generic Transcription Pathway
- Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
- Cytochrome P450 - arranged by substrate type
- Endogenous sterols
- Transcriptional regulation of white adipocyte differentiation
- Biological oxidations
- Synthesis of bile acids and bile salts
- Orphan transporters
- Defective FMO3 causes Trimethylaminuria (TMAU)
- Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
- Fatty acid, triacylglycerol, and ketone body metabolism
- Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
- Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
- Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
- Recycling of bile acids and salts
- Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
- REV-ERBA represses gene expression
- Defective CYP1B1 causes Glaucoma
- Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
- Mitochondrial biogenesis
- Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
- Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
- Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
- Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
- Synthesis of bile acids and bile salts via 27-hydroxycholesterol
- Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
- Defective MAOA causes Brunner syndrome (BRUNS)
- Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Activation of gene expression by SREBF (SREBP)
- Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Transcriptional activation of mitochondrial biogenesis
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
|
|
|
BRCA1 and KAT5 |
breast cancer 1, early onset |
K(lysine) acetyltransferase 5 |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- Chromatin modifying enzymes
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
- HATs acetylate histones
|
|
|
|
|
BRCA1 and MSH2 |
breast cancer 1, early onset |
mutS homolog 2 |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
- Mismatch Repair
|
|
|
|
|
BRCA1 and MSH3 |
breast cancer 1, early onset |
mutS homolog 3 |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Mismatch Repair
|
|
|
|
|
BRCA1 and CEP57L1 |
breast cancer 1, early onset |
centrosomal protein 57kDa-like 1 |
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
|
|
|
|
|